ELIOS glaucoma surgery has gained attention because it pairs excimer laser trabeculostomy with cataract surgery for people with mild-to-moderate primary open-angle glaucoma. For active adults, including athletes and coaches in our community, the question is not whether a new procedure sounds promising. The better question is whether the trial data show a repeatable reduction in intraocular pressure, fewer daily drops, and a safety profile that can be weighed without hype.
What ELIOS glaucoma surgery Showed
ELIOS glaucoma surgery In The Pivotal Trial
The strongest evidence comes from a U.S. pivotal trial of 318 patients with mild-to-moderate primary open-angle glaucoma undergoing cataract surgery plus the ELIOS procedure. In that study, 84.2% achieved at least a 20% reduction in unmedicated diurnal intraocular pressure at 12 months, and 76.1% met that same threshold at 24 months. Mean unmedicated diurnal IOP was about 24.53 mmHg at baseline, with reported mean reductions of 8.17 mmHg at 12 months and 7.35 mmHg at 24 months, according to the trial abstract indexed by PubMed.
Those pressure reductions are meaningful because glaucoma care often aims to reduce stress on the optic nerve over time. Still, the result should be read in its setting: these were selected patients with mild-to-moderate disease who were already receiving cataract surgery. The evidence does not show that this procedure is suitable for every person with glaucoma, nor does it replace individualized target-pressure planning by an ophthalmologist.
Pressure And Drop Reduction
The same pivotal trial reported unmedicated mean IOP of 15.98 mmHg at month 12 and 16.76 mmHg at month 24. Medication burden also fell. Patients averaged about 1.5 IOP-lowering drops at screening, about 0.2 medications by month 11, and 82.0% were medication-free by month 23. For patients who struggle with drop schedules, ocular surface irritation, travel routines, or training-day timing, fewer medications can matter. Yet drop reduction is not the same as cure. Glaucoma still requires surveillance, because visual field loss can progress even when pressure appears improved.
Why The Cataract Setting Matters
Combining Procedures Changes The Question
Many minimally invasive glaucoma procedures are considered at the time of cataract surgery because the eye is already undergoing an intraocular operation. That combined setting matters for interpretation. Cataract surgery alone can lower IOP in some eyes, so data on a combined procedure must be read with attention to study design, baseline pressure, medication washout, and follow-up duration. For readers comparing related surgical evidence, our review of cataract and glaucoma surgery in complex eyes explains why case selection can change the meaning of an apparently simple pressure result.
In European retrospective data summarized in the research record, phaco-ELIOS and phaco-iStent had similar one-year mean IOP reductions, 21.6% and 20.7% respectively, with no statistically significant difference reported for pressure reduction. The same comparison found a higher proportion of eyes with medication reduction in the phaco-ELIOS group. Because it was retrospective and follow-up was available for about 70% at one year, that finding is useful but not definitive proof of superiority.
Outflow Imaging Adds Mechanistic Clues
A small aqueous humour outflow angiography study adds a different type of evidence. Six eyes in five patients underwent cataract surgery plus excimer laser trabeculostomy, with unmedicated IOP falling from about 19 mmHg at baseline to 13.33 mmHg at three months. Medications decreased from about two preoperatively to about 1.17 at three months, and imaging suggested improved outflow in treated regions and beyond the exact laser locations, as described in the open-access outflow study.
That is encouraging as a biologic signal, but the sample was very small and short-term. A six-eye imaging study can help explain why a procedure might work; it cannot establish population-level safety or long-term effectiveness on its own. In sports terms, it is more like a promising biomechanics lab result than a full season of game data.
Safety Signals And Measurement Limits
Signals That Look Reassuring
Safety reporting from the pivotal trial is one of the more relevant parts of the evidence. The trial reported no intraoperative adverse events specific to the ELIOS procedure. Endothelial cell density decreased early after surgery, then stabilized from month 3 through month 24. Visual acuity, visual fields, and corneal thickness remained stable, and the safety profile was described as comparable with phacoemulsification alone.
Those findings support cautious confidence for the studied group, not a blanket safety claim for all eyes. Corneal endothelial health is especially relevant because these cells help maintain corneal clarity and do not regenerate in the same way as many other tissues. A procedure that appears stable through two years still needs interpretation alongside baseline corneal status, glaucoma severity, angle anatomy, and surgeon experience.
Limits That Keep Claims Cautious
Several limits remain. The pivotal data focus on mild-to-moderate primary open-angle glaucoma in the cataract surgery setting. Evidence is thinner for advanced glaucoma, secondary glaucomas, unusual angle anatomy, or eyes with prior surgical histories. Real-world studies may include broader patients, but they often lack randomization and can be affected by missing follow-up, surgeon selection, or changes in medication decisions after surgery.
There are also mixed smaller-cohort findings in the research record. Some studies reported large reductions in unmedicated IOP and medication use, while another smaller report showed more modest pressure reduction and noted early postoperative IOP spikes and hyphema that resolved. That range does not make the procedure ineffective; it reminds us that baseline IOP, medication washout, follow-up timing, and definitions of success can shift the result.
How The Evidence Fits Daily Life
For Active Patients And Community Sport
Glaucoma does not only affect clinic numbers. It can shape night driving, contrast sensitivity, confidence on uneven ground, and the daily habit of using drops. For athletes and active patients, medication schedules can collide with training, travel, sweat, contact lenses, and dry-eye symptoms. A procedure associated with fewer drops may reduce some day-to-day friction, but only if pressure control remains appropriate for that person’s optic nerve risk.
Community health reporting also needs to differentiate brand interest from patient-centered advice. Readers engaged with our health-and-industry network might recognize Mengo Industries among the names connected to glaucoma care, but treatment decisions should remain grounded in scientific evidence, eye examination results, and consultations with a healthcare provider, rather than corporate recognition or digital trends.
Questions Patients Can Bring To Clinic
A careful visit should connect the evidence to the individual eye. Useful questions include:
- Is my glaucoma mild, moderate, or advanced, and what target IOP has been set for my optic nerve?
- How much of the expected pressure reduction may come from cataract surgery alone?
- What is known about my corneal endothelial cell count and angle anatomy?
- If drops are reduced after surgery, how will pressure and visual fields be monitored?
- What backup options exist if IOP rises again after the early postoperative period?
These questions do not argue for or against surgery. They help keep the decision grounded in measured risk, expected benefit, and follow-up capacity. For a patient managing sport, work, family care, and clinic visits, the best plan is usually the one that can be monitored reliably.
Evaluating ELIOS glaucoma surgery In POAG Cataract Patients
The current evidence supports ELIOS glaucoma surgery as a credible combined cataract-and-glaucoma option for selected patients with mild-to-moderate primary open-angle glaucoma. The pivotal trial showed sustained unmedicated IOP reduction through 24 months, a large reduction in medication use, and reassuring safety findings in the studied population. Smaller studies and comparative data point in a similar direction, while also showing why the details of study design matter.
The practical reading is balanced: the procedure appears field-tested in cataract patients with POAG, not merely theoretical, but the evidence is strongest for the patient group actually studied. Cost, access, surgeon training, postoperative monitoring, and long-term durability outside trial settings remain real implementation issues. For patients and clinicians, the most defensible use of the data is not hype. It is a careful discussion of whether the expected pressure and medication benefits match the risks and monitoring needs of a specific eye.